state imbalance in pulmonary epithelial cells (2,3). Currently, there is no effective treatment for this endstage lung fibrosis disease. However, some FDA-approved therapeutic agents, including pirfenidone and nintedanib, can clearly reduce the average decrease in the function of the lung in the IPF patients (3,4).Current studies have investigated whether the pathogenesis of IPF is related to chronic epithelial injury that leads to abnormalities of the wound healing process, and both fibroblast proliferation and activation, rather than